NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage antiviral drug developer, announced that its broad-spectrum antiviral candidate NV-387 warrants evaluation as a potential treatment option for the rapidly expanding Bundibugyo strain Ebola outbreak in Africa. The company noted the absence of approved vaccines or therapies specifically targeting the virus strain.
NV-387’s host-targeted antiviral mechanism and oral formulation could offer potential advantages in outbreak settings where treatment delivery and healthcare worker safety are critical. The drug is already being prepared for a Phase II clinical trial in the Democratic Republic of Congo for mpox, which could support near-term regional availability if found effective against Ebola. According to the company, this existing clinical pathway may accelerate deployment in affected regions.
NanoViricides’ lead drug candidate NV-387 is a broad-spectrum antiviral designed to treat respiratory viral infections including RSV, COVID-19, Long COVID, and influenza, as well as mpox/smallpox and measles. The company’s platform technology is based on TheraCour nanomedicine technology, licensed from TheraCour Pharma, Inc. The company holds exclusive licenses for multiple viral diseases, including Ebola/Marburg viruses.
The announcement comes as the World Health Organization reports a growing outbreak of Bundibugyo ebolavirus in Uganda, with no specific treatments or vaccines currently approved. The company’s press release highlights that NV-387’s mechanism of action targets host cell pathways, potentially making it effective against multiple viral strains and reducing the likelihood of resistance.
Investors can find the latest news and updates regarding NNVC in the company’s newsroom at https://ibn.fm/NNVC. The full press release is available at https://ibn.fm/aSF5Z.
NanoViricides is a clinical stage company creating special purpose nanomaterials for antiviral therapy. Its business model involves licensing technology from TheraCour Pharma Inc. for specific application verticals. The company cautions that drug development is lengthy and requires substantial capital, and there can be no assurance that any of its pharmaceutical candidates will show sufficient effectiveness and safety for human clinical development.
